Collectively, this work has identified a subset of BRAF inhibitor resistant melanomas defined by epigenetic silencing of PGC1α that emerge during chronic treatment, with metastatic traits (invasion, anchorage independent survival, and in vivo metastatic spread), but acquire a collateral vulnerability towards HMGCR-inhibitor treatment. Here, HMGCR is linked to melanoma.